Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Invivyd, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW HAVEN, CONN., NOV. 25, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE ON TUESDAY, DECEMBER 2, 2025, AT 2:35 P.M. ET IN MIAMI, FL.

INVIVYD TO PARTICIPATE AT THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE

NEW HAVEN, CONN., NOV. 24, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED IT HAS IDENTIFIED AND NOMINATED FOR PRECLINICAL DEVELOPMENT A POTENTIALLY BEST-IN-CLASS MONOCLONAL ANTIBODY CANDIDATE FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) AMONG NEONATES, INFANTS, AND CHILDREN. INVIVYD'S INVESTIGATIONAL ANTIBODY, VBY329, WAS GENERATED BY INVIVYD'S PROPRIETARY ANTIBODY DISCOVERY TECHNOLOGY, TARGETED AT HIGH VALUE INFECTIOUS DISEASES. RSV IS A COMMON RESPIRATORY ILLNESS AND IS THE LEADING CAUSE OF HOSPITALIZATION FOR INFANTS IN THE UNITED STATES.

INVIVYD ANNOUNCES SELECTION OF POTENTIAL BEST-IN-CLASS RSV ANTIBODY CANDIDATE VBY329; TARGETING 2H 2026 IND READINESS

NEW HAVEN, CONN., NOV. 17, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (INVIVYD) (NASDAQ: IVVD) TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 44,000,000 SHARES OF ITS COMMON STOCK AT AN OFFERING PRICE OF $2.50 PER SHARE AND, TO CERTAIN INVESTORS, IN LIEU OF COMMON STOCK, PRE-FUNDED WARRANTS TO PURCHASE 6,000,000 SHARES OF ITS COMMON STOCK AT A PRICE OF $2.4999 PER PRE-FUNDED WARRANT. THE GROSS PROCEEDS FROM THIS OFFERING ARE EXPECTED TO BE APPROXIMATELY $125.0 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES PAYABLE BY INVIVYD. THE PURCHASE PRICE PER SHARE OF EACH PRE-FUNDED WARRANT REPRESENTS THE PER SHARE OFFERING PRICE FOR THE COMMON STOCK, MINUS THE $0.0001 PER SHARE EXERCISE PRICE OF EACH SUCH PRE-FUNDED WARRANT. ALL OF THE SHARES AND PRE-FUNDED WARRANTS ARE BEING OFFERED BY INVIVYD. IN ADDITION, INVIVYD HAS GRANTED THE UNDERWRITERS AN OPTION FOR A PERIOD OF 30 DAYS TO PURCHASE UP TO AN ADDITIONAL 7,500,000 SHARES OF INVIVYD COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT NOVEMBER 19, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

INVIVYD ANNOUNCES PRICING OF $125 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

NEW HAVEN, CONN., NOV. 17, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (INVIVYD) (NASDAQ: IVVD) TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF SHARES OF ITS COMMON STOCK. IN ADDITION, INVIVYD INTENDS TO GRANT THE UNDERWRITERS AN OPTION FOR A PERIOD OF 30 DAYS TO PURCHASE UP TO AN ADDITIONAL 15% OF THE SHARES OF INVIVYD COMMON STOCK SOLD IN THE PUBLIC OFFERING AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL OF THE SHARES ARE BEING OFFERED BY INVIVYD. THE OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

INVIVYD ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

NEW HAVEN, CONN., NOV. 06, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED RECENT BUSINESS HIGHLIGHTS.

INVIVYD REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

NEW HAVEN, CONN., NOV. 03, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DELIVERING PROTECTION FROM SERIOUS VIRAL INFECTIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL HOST A CONFERENCE CALL ON THURSDAY, NOVEMBER 6, 2025, AT 8:30 A.M. ET TO DISCUSS ITS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE.

INVIVYD TO HOST THIRD QUARTER 2025 FINANCIAL RESULTS AND CORPORATE UPDATE CALL ON NOVEMBER 6, 2025

NEW HAVEN, CONN., OCT. 28, 2025 (GLOBE NEWSWIRE) -- WHAT: INVIVYD, INC. (NASDAQ: IVVD) IS HOSTING THE PREVIOUSLY ANNOUNCED LIVE WEBCAST TO PRESENT AN OVERVIEW OF THE COMPANY'S REVOLUTION CLINICAL PROGRAM, INVIVYD'S DEVELOPMENT PROGRAM FOR VYD2311, A VACCINE-ALTERNATIVE MONOCLONAL ANTIBODY CANDIDATE FOR THE PREVENTION OF COVID. THE SESSION WILL FEATURE KEY MEMBERS OF THE INVIVYD TEAM.

INVIVYD TO HOST WEBCAST ON THE REVOLUTION CLINICAL PROGRAM FOR VYD2311, A VACCINE-ALTERNATIVE ANTIBODY TO PREVENT COVID

NEW HAVEN, CONN., OCT. 06, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS CLEARED THE COMPANY'S INVESTIGATIONAL NEW DRUG (IND) APPLICATION AND PROVIDED FEEDBACK TO ADVANCE THE COMPANY'S REVOLUTION CLINICAL PROGRAM, INVIVYD'S DEVELOPMENT PROGRAM FOR VYD2311, A VACCINE ALTERNATIVE MONOCLONAL ANTIBODY CANDIDATE FOR THE PREVENTION OF COVID.

INVIVYD ANNOUNCES U.S. IND CLEARANCE AND ALIGNMENT WITH U.S. FDA ON PIVOTAL CLINICAL PROGRAM FOR VYD2311, A VACCINE-ALTERNATIVE ANTIBODY TO PREVENT COVID

NEW HAVEN, CONN., SEPT. 24, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED THE APPOINTMENT OF PAUL B. BOLNO, M.D., TO ITS BOARD OF DIRECTORS AND AS A MEMBER OF THE COMPENSATION COMMITTEE. DR. BOLNO IS THE PRESIDENT AND CEO OF WAVE LIFE SCIENCES, A CLINICAL-STAGE BIOTECHNOLOGY COMPANY, AND HAS SERVED IN THOSE ROLES SINCE 2013.

INVIVYD APPOINTS PAUL B. BOLNO, M.D.

NEW HAVEN, CONN., SEPT. 17, 2025 (GLOBE NEWSWIRE) -- INVIVYD, INC. (NASDAQ: IVVD) TODAY ANNOUNCED THE APPOINTMENT OF KRISTIE KUHL AS CHIEF COMMUNICATIONS OFFICER. MS. KUHL WILL LEAD THE COMPANY'S COMMUNICATIONS AND PATIENT ADVOCACY EFFORTS AS INVIVYD ADVANCES ITS MISSION OF PROVIDING MONOCLONAL ANTIBODIES FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASE.

Invivyd, Inc.

IVVD

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Invivyd, Inc.

IVVD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IVVD